Antiviral Activity of The Preparation Meflokhin® Against COVID-19

The COVID-19 virus has caused a global emergency and has attracted the attention of healthcare professionals and the public around the world. The significant increase in the number of new cases of infection with this virus demonstrates the relevance of the search for drugs that are effective against this pathogen. The aim of this work was to evaluate the antiviral efficacy of Mefloquin® against COVID-19. The antiviral efficacy of Mefloquin® against the new pandemic virus SARS-CoV-2 was studied in in vitro experiments in Vero C1008 cell culture and in vivo on Syrian golden hamsters. The results of the study revealed that the drug Mefloquine® at a concentration of 2.0 µg ml-1, when applied after infection of cells, suppresses the reproduction of the SARS-CoV-2 virus by 1.7–1.9 lg, the inhibition rate is about 99%. When using Mefloquine, pathological changes in the lung tissue were less pronounced than in the control group. 6 days after infection, it was shown that when using Mefloquine, there was a statistically significant decrease in viral load in the lungs of infected Syrian golden hamsters, with an inhibition rate of 95.5%.

1. Su S., Wong G., Shi W. et al. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol. 2016; 24: 490–502. doi: 10.1016/j.tim.2016.03.003. Epub 2016 Mar 21.

2. Cui J., Li F., Shi Z.L. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019; 17: 181–192. doi: 10.1038/s41579-018-0118-9.

3. Zhong N.S., Zheng B.J., Li Y.M. et al. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People’s Republic of China, in February, 2003. Lancet. 2003; 362: 1353–1358. doi: 10.1016/s0140-6736(03)14630-2.

4. Ksiazek T.G., Erdman D., Goldsmith C.S. et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med. 2003; 348: 1953–1966. doi: 10.1056/NEJMoa030781. Epub 2003 Apr 10.

5. Drosten C., Günther S., Preiser W. et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 2003; 348: 1967–1976. doi: 10.1056/NEJMoa030747. Epub 2003 Apr 10.

6. Zaki A.M., van Boheemen S., Bestebroer T.M., Osterhaus A.D., Fouchier R.A. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012; 367: 1814–1820. doi: 10.1056/NEJMoa1211721.

7. Desforges M., Le Coupanec A., Dubeau P., Bourgouin A., Lajoie L., Dubé M., Talbot P.J. Human coronaviruses and other respiratory viruses: underestimated opportunistic pathogens of the central nervous system? Viruses. 2019 Dec 20; 12 (1). 14. doi: 10.3390/v12010014.

8. Wong G., Liu W., Liu Y., Zhou B., Bi Y., Gao G.F. MERS, SARS, and Ebola: the role of super-spreaders in infectious disease. Cell Host Microbe. 2015; 18: 398–401. doi: 10.1016/j.chom.2015.09.013.

9. Руководство по экспериментальному (доклиническому) изучению новых фармакологических веществ. М.: Минздрав РФ, 2005. [Rukovodstvo po eksperimental'nomu (doklinicheskomu) izuchenijyu novykh farmakologicheskikh veshchestv. Moscow: Minzdrav RF, 2005. (in Russian)]

10. Руководство по проведению доклинических исследований лекарственных средств. М., ФГБУ «НЦЭСМП» Минздравсоцразвития России, 2012. [Rukovodstvo po provedenijyu doklinicheskikh issledovanij lekarstvennykh sredstv. Moscow: FGBU «NTsESMP»Minzdravsotsrazvitiya Rossii, 2012. (in Russian)

11. Ашмарин И.П., Воробьев А.А. Статистические методы в микробиологических исследованиях. Ленинград: Медгиз., 1962; 180. [Ashmarin I.P., Vorob'ev A.A. Statisticheskie metody v mikrobiologicheskikh issledovaniyakh. Leningrad: Medgiz., 1962; 180. (in Russian)]

12. Беленький М.Л. Элементы количественной оценки фармакологического эффекта. Ленинград: Медгиз, 1963; 170. [Belen'kij M.L. Elementy kolichestvennoj otsenki farmakologicheskogo effekta. Leningrad: Medgiz, 1963; 170. (in Russian)]